Product Information
FUROSEMIDE 40 MG/4 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $0.2525 per ML under NDC 63323028026. Its NADAC has been published 177 times since May 17, 2023.
FDA first approved this application on May 22, 1984. Its Orange Book therapeutic-equivalence code is AP.
Strength
10 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323028026
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
FUROSEMIDEApproval Type
New Drug (NDA)
FDA Application
NDA018902FDA Approved
5/22/1984
TE Code
AP
On Market Since
7/12/2000
Pharmacological Classes
Price Statistics
The NADAC for FUROSEMIDE 40 MG/4 ML VIAL has been published 177 times since May 17, 2023, and over the history we have for it it has declined 26.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2525 per ML |
|---|---|
| All-time high | $0.5940 (Apr 10, 2024) |
| All-time low | $0.2231 (Jun 18, 2025) |
| 52-week high | $0.3500 |
| 52-week low | $0.2231 |
| Median price | $0.3026 |
| Average price | $0.3238 |
| Largest weekly change | +72.8% (Nov 22, 2023) |
| Weeks tracked | 177 |
| Tracking since | May 17, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
FUROSEMIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FUROSEMIDE 40 MG/4 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for FUROSEMIDE 40 MG/4 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $0.2525 per ML (NDC 63323028026), effective Sep 30, 2026.
How has the price of FUROSEMIDE 40 MG/4 ML VIAL changed over time?
Over the history we have for it, the NADAC for FUROSEMIDE 40 MG/4 ML VIAL has declined 26.5%. It has been tracked across 177 weekly CMS publications since May 17, 2023.
What are the highest and lowest recorded NADAC prices for FUROSEMIDE 40 MG/4 ML VIAL?
Since May 17, 2023, the NADAC for FUROSEMIDE 40 MG/4 ML VIAL has ranged from a low of $0.2231 (Jun 18, 2025) to a high of $0.5940 (Apr 10, 2024), with a median of $0.3026 per ML.
Are there cheaper alternatives to FUROSEMIDE 40 MG/4 ML VIAL?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FUROSEMIDE 40 MG/4 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures FUROSEMIDE 40 MG/4 ML VIAL?
FUROSEMIDE 40 MG/4 ML VIAL (NDC 63323028026) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.